Portola Pharmaceuticals Inc. | Ownership
Companies that own Portola Pharmaceuticals Inc.
Wellington Management Co. LLP
9,017,508
13.65%
10,993
0.05%
06/30/2018
The Vanguard Group, Inc.
5,534,662
8.38%
184,924
0.01%
06/30/2018
Temasek Holdings Pte Ltd. (Investment Management)
5,174,168
7.83%
290,600
0.34%
06/30/2018
Partner Fund Management LP
5,148,578
7.79%
-250,377
2.66%
06/30/2018
BlackRock Fund Advisors
4,778,632
7.23%
477,095
0.01%
06/30/2018
SSgA Funds Management, Inc.
2,828,579
4.28%
-222,726
0.01%
06/30/2018
Cadian Capital Management LP
2,280,201
3.45%
1,039,257
3.06%
06/30/2018
Fidelity Management & Research Co.
1,970,485
2.98%
-7,600
0.01%
06/30/2018
Deerfield Management Company LP
1,446,633
2.19%
1,446,633
1.23%
06/30/2018
Zevenbergen Capital Investments LLC
1,253,625
1.9%
424,100
1.17%
06/30/2018
| Address |
270 East Grand Avenue
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.portola.com |
| Updated |
07/08/2019 |
| Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J. |
